Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes.
Catherine M ViscoliMelanie Jane DaviesKamlesh Khunti F MedSciPrabhav TrivediJyothis T GeorgeIsabella ZwienerOdd Erik JohansenNaveed SattarPublished in: Diabetes, obesity & metabolism (2020)
Empagliflozin, as add-on to metformin, decreases HbA1c and BW, particularly in patients with higher HbA1c and BW baseline values, and effectively lowers SBP.